Effect of chlorpromazine on rat placenta development

Area of Science:

• Reproductive toxicology
• Developmental biology
• Histopathology

Background:

• Chlorpromazine is an antipsychotic medication with potential teratogenic effects.
• Placental development is crucial for fetal well-being.
• Understanding drug-induced placental changes is vital for risk assessment.

Purpose of the Study:

• To investigate the sequential histopathological effects of chlorpromazine on rat placentas.
• To determine the dose-dependent impact of chlorpromazine on placental development and function.
• To correlate placental alterations with fetal outcomes such as resorption and growth restriction.

Main Methods:

• Rats were administered chlorpromazine intraperitoneally on gestational day 14 at 50 and 100 mg/kg.
• Placentas were collected on gestational days 14.5, 15, 17, and 21 for analysis.
• Histopathological examination focused on the labyrinth and basal zones of the placenta.
• Fetal resorption rates, embryo/fetal weights, and placental weights were recorded.

Main Results:

• Chlorpromazine exposure increased fetal resorption rates in a dose-dependent manner.
• Significant reductions in embryo/fetal and placental weights were observed.
• Histopathological findings included trophoblast apoptosis, labyrinth zone hypoplasia, and impaired glycogen cell development in the basal zone.
• Delayed development and cystic degeneration of glycogen cell islands, leading to metrial gland hypoplasia, were noted.

Conclusions:

• Chlorpromazine induces significant dose-dependent placental histopathological changes in rats.
• These placental alterations, including trophoblast and glycogen cell damage, contribute to adverse fetal outcomes.
• The study highlights the potential risks of chlorpromazine during pregnancy and the importance of placental examination in toxicological studies.